

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6600076

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
APEX THERAPEUTICS, INC.	03/12/2021
RECEIVING PARTY DATA	
Name:	APEXIAN PHARMACEUTICALS, INC.
Street Address:	20 NORTH MERIDIAN STREET
Internal Address:	SUITE 801
City:	INDIANAPOLIS
State/Country:	INDIANA
Postal Code:	46204
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9193700
CORRESPONDENCE DATA	
Fax Number:	(314)259-3939
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3148630800
Email:	susan.brooks@stinson.com
Correspondent Name:	STINSON LLP
Address Line 1:	7700 FORSYTH BLVD.
Address Line 2:	SUITE 1100
Address Line 4:	ST. LOUIS, MISSOURI 63105
ATTORNEY DOCKET NUMBER:	3003527.0422
NAME OF SUBMITTER:	JEANNIE M. BOETTLER
SIGNATURE:	/Jeannie M. Boettler/
DATE SIGNED:	03/15/2021
Total Attachments: 6	
source=Assignment with Schedule A#page1.tif	
source=Assignment with Schedule A#page2.tif	
source=Assignment with Schedule A#page3.tif	
source=Assignment with Schedule A#page4.tif	

source=Assignment with Schedule A#page5.tif

source=Assignment with Schedule A#page6.tif

In the United States Patent and Trademark Office

Assignment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

WHEREAS Apex Therapeutics, Inc., or through any of its subsidiaries, affiliates, and previous aliases (hereinafter referred to as Assignor), is owner of full and exclusive right, title and interest to said inventions and under said Letters Patent or similar legal protection for inventions included in the attached Schedule A.


AND WHEREAS Apexian Pharmaceuticals, Inc., (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said inventions and under said Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that for good and valuable consideration, the receipt of which is hereby acknowledged, the Assignor hereby sell, assign and transfer to the Assignee the full and exclusive right, title and interest to said inventions and to any and all Letters Patents or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said inventions by said applications or any continuation, continuation-in-part, divisional, renewal, substitute, re-examination, conversion or reissue thereof, including all extensions thereof, or any legal equivalent thereof in any foreign country for the full term or terms for which the same may be granted, including any and all convention rights.

The Assignor hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale.

The Assignor further covenants that the Assignor will promptly provide, upon written request, Assignee with all pertinent facts and documents relating to said application, said inventions and said Letters Patent and legal equivalents in foreign countries as may be known and accessible to the Assignor and that it will promptly execute and deliver to Assignee or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue, extend and enforce said application, said inventions and said Letters Patent and said equivalents thereof in any foreign country which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, Assignor has executed this document on the date indicated below:



3.12.2021

Date:

Name: Mark R. Kelley, PhD.
Title: Chief Scientific Officer, Apexian Pharmaceuticals

Schedule A

Docket No.	Patent No.	Application No.	Title	Reel/Frame
2011-011-10 (3003527- 0422	9,193,700	14/119,949	QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES	028819/0678 033418/0525 031718/0945
2011-011- 20(3003527- 0415	10,154,973	15/868,245	QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES	028819/0678 033418/0525 031718/0945


Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "APEX THERAPEUTICS, INC.", CHANGING ITS NAME FROM "APEX THERAPEUTICS, INC." TO "APEXIAN PHARMACEUTICALS, INC.", FILED IN THIS OFFICE ON THE ELEVENTH DAY OF OCTOBER, A.D. 2016, AT 11:24 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



4538355 8100
SR# 20166151091

You may verify this certificate online at corp.delaware.gov/authver.shtml

A handwritten signature in black ink, appearing to read "JB", is written over a horizontal line. Below the line, the text "Jeffrey W. Bullock, Secretary of State" is printed.

Authentication: 203142102
Date: 10-11-16

PATENT
REEL: 055587 FRAME: 0371

**CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
APEX THERAPEUTICS, INC.**

Apex Therapeutics, Inc., a Delaware corporation (the "Corporation"), hereby certifies as follows:

FIRST: Article FIRST of the Amended and Restated Certificate of Incorporation of the Corporation, as subsequently amended (the "Certificate of Incorporation"), is hereby amended and restated in its entirety to read as follows:

"FIRST: The name of this corporation is Apexian Pharmaceuticals, Inc. (the "Corporation")."

SECOND: The first paragraph of Article FOURTH of the Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:

"FOURTH. The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 8,000,000 shares of common stock, \$0.001 par value per share ("Common Stock"), and (ii) 5,500,000 shares of preferred stock, par value \$0.001 per share ("Preferred Stock")."

THIRD: The first paragraph of Part B of Article FOURTH of the Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:

"B. PREFERRED STOCK

Five million five hundred thousand (5,500,000) shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated "Series A Preferred Stock" with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to "Sections" in this Part B of this Article Fourth refer to sections of Part B of this Article Fourth."

FOURTH: The foregoing amendments have been duly adopted in accordance with Section 242 of the Delaware General Corporation Law.

FIFTH: This Certificate of Amendment shall be effective upon filing with the Delaware Secretary of State.

*[Remainder of Page Intentionally Blank;
Signature to Follow]*

In Witness Whereof, the undersigned has executed this Certificate of Amendment as of October 11, 2016.

APEX THERAPEUTICS, INC.

By: /s/ Steve Carchedi
Steve Carchedi, Chief Executive Officer

*[Signature Page to Certificate of Amendment to
Amended and Restated Certificate of Incorporation]*

State of Delaware

Annual Franchise Tax Report

CORPORATION NAME			TAX YR.
APEXIAN PHARMACEUTICALS, INC.			2018
FILE NUMBER	INCORPORATION DATE	RENEWAL/REVOCATION DATE	
4538355	2008/04/24		
PRINCIPAL PLACE OF BUSINESS			PHONE NUMBER
20 NORTH MERIDIAN STREET, STE 801 INDIANAPOLIS, IN 46204			(317) 263-3709
REGISTERED AGENT			AGENT NUMBER
THE CORPORATION TRUST COMPANY CORPORATION TRUST CENTER 1209 ORANGE ST WILMINGTON DE 19801			9000010
AUTHORIZED STOCK		DESIGNATION/ STOCK CLASS	NO. OF SHARES
BEGIN DATE	END DATE		PAR VALUE/ SHARE
2017/11/09		COMMON	10,500,000 .0010000000
		PREFERRED	8,000,000 .0010000000
OFFICER		NAME	TITLE
STEVE		CARCHEDI	CEO
		STREET/CITY/STATE/ZIP	
		20 NORTH MERIDIAN STREET, STE 801 INDIANAPOLIS, IN 46204	
DIRECTORS		NAME	STREET/CITY/STATE/ZIP
JOHN H BARNARD			20 NORTH MERIDIAN STREET STE 801 INDIANAPOLIS, IN 46204
MARTIN F HASLANGER			20 NORTH MERIDIAN STREET STE 801 INDIANAPOLIS, IN 46204
MARK R KELLY			20 NORTH MERIDIAN STREET STE 801 INDIANAPOLIS, IN 46204
HOMER L PEARCE			20 NORTH MERIDIAN STREET STE 801 INDIANAPOLIS, IN 46204
<p><i>NOTICE: Pursuant to 8 Del. C. 502(b), If any officer or director of a corporation required to make an annual franchise tax report to the Secretary of State shall knowingly make any false statement in the report, such officer or director shall be guilty of perjury.</i></p>			
AUTHORIZED BY (OFFICER, DIRECTOR OR INCORPORATOR)		DATE	TITLE
JOHN H BARNARD		2019/02/19	COB
20 NORTH MERIDIAN STREET, STE 801 INDIANAPOLIS, IN 46204 US			